ArticleThe Journal of clinical investigation2020

A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.

Balamayoora Theivanthiran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.